What is the age group for which Milvamuttide Injection is suitable?

Mifamurtide injection (Mifamurtide) is mainly used to treat a rare and highly malignant bone tumor - osteosarcoma . It is especially suitable for patients with high-grade osteosarcoma who have undergone complete surgical resection without distant metastasis. Its applicable groups are mainly concentrated in children, adolescents and young adults. Medical research and clinical trial data show that its safety and effectiveness are most clear among patients aged between 2 and 30 years old.

Osteosarcoma is usually more common in adolescents during the period of rapid growth and development. Milvamuttide has shown the potential to prolong survival in the treatment of newly diagnosed patients and has therefore been included in the list of pediatric medicines approved by the European Medicines Agency (EMA). The treatment concept is to activate the body's innate immune system, especially the anti-tumor ability of monocytes/macrophages, to further eliminate minimal residual lesions in the body after surgery and chemotherapy and prevent disease recurrence. Especially in young patients with active immune systems and strong recovery ability, the immunomodulatory effect of this drug is more obvious.

There is currently no sufficient evidence to support the use of this drug for people over 30 years old. This also means that the use of this drug in middle-aged and elderly osteosarcoma patients needs to be extremely cautious, and the decision whether it is suitable for use must be strictly evaluated by a professional oncologist. At the same time, although patients over 2 years old are considered safe to use, body temperature, liver function, inflammatory response and other indicators still need to be closely monitored during use to deal with possible immune-related adverse reactions caused by the drug.

It is worth noting that in rare cases, some overseas treatment centers will try to use mivamutide on patients over30 years old, provided that the patient is in good physical condition and there is no more suitable alternative. However, this kind of medication falls into the category of "off-label" and needs to be carried out based on ethical review and full informed consent.

Reference materials:https://www.ema.europa.eu/en/medicines/human/EPAR/mepact